BRAINtSERS · BRAIN organoids unTanglement with SERS
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-12-01 → 2023-12-31
- Финансиране от ЕС
- 175 256 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Човешки мозъчни органоиди се анализират чрез Рамановска спектроскопия, за да се проследи биохимичното им развитие без използване на химически маркери. Това помага за по-доброто разбиране на неврологичните заболявания и създаването на терапии, съобразени с генетиката на конкретния пациент.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
BRAIN organoids unTanglement with SERS
Neurological disorders remain a leading cause of mortality due to the lack of effective treatments, which is attributed to the limitations of current research models for neurological disorders, neurodevelopment, and drug interactions in the central nervous system. In vitro monolayer cell cultures and in vivo animal models have restrictions that impede translation of research and treatment to humans. The genetic and environmental cues in animals do not match those of humans, and two-dimensional cultures lack cellular diversity and interconnectivity, particularly in brain models. Human brain organoids provide an unprecedentedly accurate model for human brain diseases and developmental programs. In addition, Brain organoids derived from hiPSCs (human induced pluripotent stem cells) can mimic the exact genetic mutations and developmental progression of a disorder derived from a patient's genome, creating great prospects for patient-specific treatments and transplantation therapy. However, current techniques for analyzing brain organoids during growth and pathology evolution, such as imaging and genomic analysis, have limitations. Fluorescent imaging requires the labeling of target molecules, which can alter their behavior and introduce artifacts, while genetic sequencing irreversibly alters the sample, making it impossible to conduct further experiments on the same material. Therefore, it is imperative, especially for brain organoid to find methodologies that can fully characterize their structural and functional properties without interfering with the development. Raman Spectroscopy, being non-invasive and label free, could address these challenges allowing to get the whole biochemical information along the development of the organoid. Specifically, the action will provide: (i) a label-free, highly sensitive technique for quantification and detection of biomolecules in brain organoids, (ii) a minimally-invasive system for cellular phenotyping, thus a non-destructive method for characterization of brain organoids during developmental stages.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Neuropsychiatric disorders and neurological diseases have a devastating impact on patients’ lives and represent a heavy social and economic load for global societies. Despite the great social and economic importance, the complex symptomatology together with the lack of objective analysis methodology and the limitation of current biological models have made disorders difficult to classify and study. The recent development of brain organoids derived from human stem cells have enormous potential as a physiologically accurate downscaled in vitro model of the human brain. Even though this system offers promising approach for investigating the phenotypic foundation of these complex disorders, the lack of a reliable and non-disruptive system for investigating their properties limits their applicability in both basic research and pharmaceutical testing. The BRAINtSERS project aims to respond to this need combining advanced brain organoid models together with surface-enhanced Raman spectroscopy (SERS), providing a multidimensional dataset of a developing human neuronal tissue resolved both in time and space. In detail, the action will provide: (i) a label-free, highly sensitive technique for quantification and detection of biomolecules in brain organoids, (ii) a minimally-invasive system for cellular phenotyping, thus a non-destructive method for characterization of brain organoids during all developmental stages. Complementarily, the ER will deliver (iii) SERS-active bio-mimetic devices conceived for integration with organoid model and its genesis.
Оригинален текст от CORDIS (на английски).
Участници
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaКоординаторИталия
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY · CambridgeСъединени щати
Връзки
Данни: CORDIS, © Европейски съюз